chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A report was received from a health care professional on 9/29/03 concerning a female vaccinee in her 30's who experienced injection site reaction with redness and soreness, decreased appetite and mild total body ache one day after receiving Fluvirin on 9/26/03. On 9/27/03, the vaccinee experienced injection site reaction with redness and soreness, decreased appetite and mild total body ache. The events resolved on an unspecified date. There was insufficient information to determine the reporter's causality assessment. Cross reference with PJP200300732, PJP200300730. Follow up pending.
pt recv vax 1NOV96 & @17mo old 7APR97 varicella;
Pt has long hx of allergic (mild - moderate, rash and flushing) with different food preservatives and medication. Was cleared by doctor to get J&J but told to wait 30 minutes before discharge. Several minutes after getting vaccine, pt reported facial flushing and lightheadedness. Pt instructed to sit in reclined position in exam room and given bottled water (which she did not drink due to allergies to preservatives).   Physical Exam.  BP 167/95, T 96.6, RR 22, O2 95%. Lungs CTAB. Airway clear and non-edematous.   After 30 minutes, pt felt well enough to go home on own. Pt given clear ER or PCP clinic return precautions.
SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient concerned a female of unspecified age, race and ethic origin. The patient's height, and weight were not reported. The patient's past medical history included: covid-19 in AUG-2020. The patient received covid-19 vaccine ad26.cov2.s (Dose Number in Series: 1, suspension for injection, route of admin not reported, batch number: 1805022, expiry: UNKNOWN) dose was not reported, administered on 17-MAR-2021 to right arm for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, after the vaccination, the patient was sick for 5 days and experienced suspected covid-19 infection (suspected clinical vaccination failure). The patient also reported that her covid was clinically confirmed by her physician. (Dose Number in Series: 1). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected covid-19 infection and suspected clinical vaccination failure was not reported. This report was serious (Other Medically Important Condition). This report was associated with product quality complaint and reference number requested.; Sender's Comments: :20211225283-COVID-19 VACCINE AD26.COV2.S-Suspected clinical vaccination failure. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS
Chills; muscle ache\ he had intense body aches\achy throughout the night; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (muscle ache\ he had intense body aches\achy throughout the night) and CHILLS (Chills) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 005C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Apr-2021, the patient experienced MYALGIA (muscle ache\ he had intense body aches\achy throughout the night). On 30-Apr-2021, the patient experienced CHILLS (Chills). The patient was treated with IBUPROFEN ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, MYALGIA (muscle ache\ he had intense body aches\achy throughout the night) had not resolved and CHILLS (Chills) outcome was unknown.            No concomitant medication was reported. Treatment drug include Ibuprofen.   This case was linked to US-MODERNATX, INC.-MOD-2021-099481; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-099481:case for wife
Headache; sick to stomach; throwing up; bones hurt in his body; Diarrhea; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58 year-old male patient received bnt162b2 (BNT162B2), administration date 08Mar2021 14:00 (Batch/Lot number: unknown) at the age of 58 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious), outcome "unknown", described as "Headache"; ABDOMINAL DISCOMFORT (non-serious), outcome "unknown", described as "sick to stomach"; VOMITING (non-serious), outcome "unknown", described as "throwing up"; SKELETAL INJURY (non-serious), outcome "unknown", described as "bones hurt in his body"; DIARRHOEA (non-serious), outcome "unknown", described as "Diarrhea". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.  Additional information: Caller got the shot yesterday at 2 o'clock to keep from getting the coronavirus. He has had 45 clients who died from coronavirus who were not lucky enough to get it. All kinds of stuff are going on. Patient was wondering if it is safe. He even cuts peoples hair that work for Pfizer. He has heard the second shot is worse. He was wondering if he can take Tylenol or Aspirin for these side effects.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Redness in right arm, below site of injection, began to turn red at about 15 minutes after the vaccine injection was administered.  Took 20mg of Prednisone orally at this point (and had premedicated with 50mg of Benadryl prior to injection).  Vital Signs remained within normal limits and I was allowed to leave the clinic with the instructions to continue taking the Prednisone until the prescribe doses doses were completed.  During the next 72 hours there was a progression of the same symptoms as I experienced with the first dose, except that there was not the cytokine storm coma like effect; instead, there was no ability to sleep at all.  There was a lot of bone and muscle pain, difficulty breathing, swelling and redness of the right arm that extended under the armpit area and over to the sternum, chest pain and pressure in the area of the carotid artery systems, and wild swings of dysautonomia, chills, nausea, and vomiting
Vesicle in varies stages of healing on the body, arm, leg. No Tx.
Local 16 x 9 cm erythematous lesion around the injection site, warm to touch, no fissures or discharge noted.
Extreme dizziness and ringing in his ears. When taken to the hospital he was transferred to a hospital  for possible stroke, due to eye fluttering.
Approximately 4-5 hours after the shot, her arm went numb and she couldn't use it for about 3 days. The numbness is slowly wearing off and she is able to use the arm.
General Fatigue; Limited mobility of right arm, unable to lift arm to normal heights; unable to lift arm to normal heights; pain at injection site; redness and swelling of right hand; redness and swelling of right hand; weakness in right hand including weakened grip; sluggish mobility; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 25 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 21Oct2021 14:30 (Lot number: FF8841) at the age of 25 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing), notes: other medical history: Asthma; "COVID-19" (unspecified if ongoing), notes: if covid prior vaccination: Yes; "Allergy" (unspecified if ongoing), notes: Relevant past drug history:, Name of Drug as Reported: No, Reaction: Allergy. Concomitant medication(s) included: BENADRYL; CLARITINE; ALBUTEROL HFA. The following information was reported: FATIGUE (non-serious) with onset 21Oct2021 14:30, outcome "not recovered", described as "General Fatigue"; JOINT RANGE OF MOTION DECREASED (non-serious) with onset 21Oct2021 14:30, outcome "not recovered", described as "Limited mobility of right arm, unable to lift arm to normal heights"; AXILLARY PAIN (non-serious) with onset 21Oct2021 14:30, outcome "not recovered", described as "unable to lift arm to normal heights"; VACCINATION SITE PAIN (non-serious) with onset 21Oct2021 14:30, outcome "not recovered", described as "pain at injection site"; ERYTHEMA (non-serious), PERIPHERAL SWELLING (non-serious) all with onset 21Oct2021 14:30, outcome "not recovered" and all described as "redness and swelling of right hand"; MUSCULAR WEAKNESS (non-serious) with onset 21Oct2021 14:30, outcome "not recovered", described as "weakness in right hand including weakened grip"; SLUGGISHNESS (non-serious) with onset 21Oct2021 14:30, outcome "not recovered", described as "sluggish mobility". Therapeutic measures were not taken as a result of fatigue, joint range of motion decreased, axillary pain, vaccination site pain, erythema, peripheral swelling, muscular weakness, sluggishness.  Additional Information: The patient administered CaOVID-19 vaccine at Facility: Pharmacy or Drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received Albuterol inhaler as a medication within 2 weeks of vaccination. Prior to vaccination, the patient was diagnosed with COVID. Since the vaccination, the patient has not been tested for COVID-19.  Follow-up (27Oct2021): Follow-up attempts are completed. No further information is expected.  No follow-up attempts are possible. No further information is expected.
2 weeks and 2 days after vaccine I developed shingles along my hairline and upper right forehead
on 3-17-07 patient woke up in the AM with swelling redness and fever at injection site. On 3/18/07 swelling had gone down slightly.
?Freezing cold feeling? after 24 of the vaccination shot, 2 nd dose COVID-19
Developed red, hot, swollen, itchy rash at the injection site after approx. 5 days from the date of the first dose of vaccine.  Full body chills, extreme exhaustion, limited mobility in the limb.
Two days after taking the second dose of the covid-19 vaccine when I tried to woke up from bed I just couldn?t. I felt so dizzy and nauseous I couldn?t stand up. I laid in bed for 45 minutes waiting for the symptoms to subside a little bit. I took me around 2 hours to feel again a little more functional. The dizziness continued for 2 more days after that event.
moderate pain in arm; moderate headache then sudden bloody nose 2 days later from right nostril with two large blood clots.  Headache remains.
Pt inadvertently vax w/ hepta B. instead of prohibit. TOR no adverse ex.
Patient received under diluted dose of covid PFizer 5-11 vaccine. No adverse effects reported at this time.
Red, hard circle at site of injection. No pain or other symptoms per pt. Advised to call dr if worsens.
pt recv vax;exp chills & fever followed by swelling & pain of lt upper arm & joint pain particularly in ankles & shoulders;apap given;lt upper arm remains red & swollen
Tired, body aches, hives, rash, itching, low grade fever, chills
Patient reported history of anxiety-induced vaso vagal reactions and emesis when receiving vaccinations. Reported feeling "dizzy" within 1 minute after receiving influenza vaccine. Became diaphoretic and vomited x3 within 2 minutes of vaccination. Rested in Fowler's position for 10 minutes post emesis. Returned to high Fowler's for 5 minutes and drank 12 oz water prior to standing. Sat in waiting area for an additional 5 minutes prior to discharge. Stated she felt "fine". Told to RTC if sx return/other reactions to vaccine.
This spontaneous report was received from a nurse refers to two patients of unknown age. On 23-MAY-2016, the patients were vaccinated with an improperly stored PROQUAD (Merck) lot # L051098, 17-JUN-2017 and M002053, 1-JUL-2017. No adverse event was reported. Additional information has been requested.
Varicella (Mild) rash (<50 lesions) without fever or complications.
Patient c/o lethargy, drippy nose, headache and increase in BP to 170/100.  Ringing in ears. No temp. Placed on HTN meds after dr. visit.  Shortness of breath with walking.
Two days after vaccination (11/12) noticed some bruising and petechiae. Had a CBC done which showed thrombocytopenia. Was admitted to the hospital for complete workup (many tests done to rule out any underlying illness which are all negative). Have had continued thrombocytopenia and also auto immune neutropenia. Was started on high dose steroid treatment and am now on second round of treatment with high dose steroids. Still undergoing treatment.
Pt. found on the floor. Pt. stated that he passes out when he gives blood or has blood drawn. Pt. stated that he had a lighter than usual breakfast. Pt. sweaty. Blood pressure and heart rated decreased from time of incident for several minutes. Pt. transported to medical center for further evaluation. Administered NSS n500 ML IV   by the medic and oral fluids 16 oz of water and kool aid - by the medic and RN on site.
Booster dose administered; subsequent titer was pos; pt titer was neg p/3 doses of Engerix-B;
Patient received 1st anthrax vaccination on 4/18/2007.  Vaccination notable for attempted vaccination with frozen vaccine, then vaccinated with new syringe without difficulty.  Patient developed neck and trapezius stiffness on side of injection within 12 hours.  Treated with Toradol 30 mg IM then Motrin and oral narcotic.  Developed photophobia and fever to 102 on 4/26/2007 (8 days after vaccination). LP performed; patient admitted to hospital for IV ceftriaxone and IV vancomycin until culture was negative for bacteria for 48 hrs. 7/20/07 Received medical records from reporter which reveal patient had neck pain & right shoulder pain on 4/19/07. DX w/ neck sprain secondary to injection trauma & muscle spasm.  Received injection for pain & trigger point injection scheduled.  RTC on 4/26/07 for fever of 102, spine pain, headache, photophobia & rash at injection site. DX w/aseptic menintitis & admitted 4/26-4/30/07.  TX w/ IV antibiotics & pain meds.  Progressed well & d/c after 72 hrs of antibiotics & neg cultures.  No meds at d/c. FINAL DX: Aseptic Meningitis & post anthrax myalgia.
Headache, 7pm 4/10/2021, currently happening Severe Dizziness (nearly to fainting), 8:30am 4/11/2021, ended 12:00 pm 4/11/2021 Tiredness, 9pm 4/10/2021, currently happening Chills, 1pm 4/11/2021, currently happening
Diagnosed with myocarditis 3 months after receiving the 2nd COVID vaccine. Symptoms included chest pain x 2 overnight.  Had upper respiratory infection 6 weeks prior to myocarditis. 2nd COVID vaccine:  1/8/21 Respiratory infection: 2/19/21 Myocarditis 4/7/21
The patient was fine immediately following the injection. I left him for about 5 minutes to get his immunization card. When I returned he was very pale and sweating profusely. He said he felt very dizzy and was quite frightened. I reached out to hold his arms and ease him to the floor when he fell backwards unconscious in the chair. I was able to keep him from falling to the ground and I called for help. He returned to consciousness after about 10 seconds and I applied a cold compress to his head and neck. He began feeling better rapidly and was able to drink water and rest comfortably. He was able to leave the area without further issue or need for medical attention
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently 85 years old male patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications.  On 14-OCT-2009, the  patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) for the long-term prevention of shingles and zoster-related conditions. On an unspecified date, the patient experienced shingles. On an unspecified date, the patient was treated by a physician for shingles. The outcome of the events shingles was not reported. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).   Additional information has been requested.
Supposed to receive the 23 and instead received another dose of Prevnar 13; This is a spontaneous report from a contactable nurse. A patient of unspecified age and gender received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13, Lot number and expiration date were not reported), with route of administration and therapy date unspecified, at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient previously took pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13) in 2018 for immunization. On an unspecified date, the patient was supposed to receive "the 23", and instead had received another dose of pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13).  Information on the batch/lot number has been requested.
SHARP STABBING HEART PAIN; This spontaneous report received from a patient concerned a 65 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included high cholesterol, non smoker, and non alcoholic, and the patient had no known allergies and no drug abuse or illicit drug usage.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1821286, expiry: unknown) dose was not reported, 1 total administered to left arm on 24-MAY-2021 at 11:00 for prophylactic vaccination. Concomitant medications included simvastatin for high cholesterol. On vaccination at about 15:00, the patient began experiencing side effect of sharp stabbing heart pain which was lasted for about 5-7 seconds. He took one low dose aspirin and was doing well now. He had reported this adverse event to the vaccine facility and was not going to see his doctor. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sharp stabbing heart pain on 24-MAY-2021. This report was serious (Other Medically Important Condition).; Sender's Comments: V0-20210551413-Covid-19 vaccine ad26.cov2.s -Sharp stabbing heart pain. This event(s) is considered un-assessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Admitted for a fever of 102.4 degrees Farenheight; Myalgia; Shortness breath; This spontaneous case was reported by a pharmacist and describes the occurrence of PYREXIA (Admitted for a fever of 102.4 degrees Farenheight) and MYALGIA (Myalgia) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included METRONIDAZOLE, CEFEPIME and VANCOMYCIN for an unknown indication.    On 01-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, the patient experienced PYREXIA (Admitted for a fever of 102.4 degrees Farenheight) (seriousness criterion hospitalization), MYALGIA (Myalgia) (seriousness criterion hospitalization) and DYSPNOEA (Shortness breath). The patient was hospitalized on 02-Mar-2021 due to MYALGIA and PYREXIA. At the time of the report, PYREXIA (Admitted for a fever of 102.4 degrees Farenheight), MYALGIA (Myalgia) and DYSPNOEA (Shortness breath) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Mar-2021, Body temperature: high (High) Fever of 104 degrees Fahrenheit temperature at home and admitted for a 102.4 degrees Fahrenheit.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information were given.  Patient did not had myocarditis or pericarditis. Cause of symptoms was not determined. Reporter mentioned that hospital lists a reason for admission that is different from the vaccine side effect. Company comment:This is case concerning a female patient of 64-year-old with no medical history, who experienced the unexpected serious events of Pyrexia and Myalgia (seriousness criterion Hospitalization) which occurred one day after patient received the second dose of mRNA-1273 and outcome was reported as unknown. Patient required hospitalization however, there is no medical assessment or treatment information provided. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This is case concerning a female patient of 64-year-old with no medical history, who experienced the unexpected serious events of Pyrexia and Myalgia (seriousness criterion Hospitalization) which occurred one day after patient received the second dose of mRNA-1273 and outcome was reported as unknown. Patient required hospitalization however, there is no medical assessment or treatment information provided. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
The patient was treated for shingles, postherpetic neuralgia and other zozter-related conditions; The patient was treated for shingles, postherpetic neuralgia and other zozter-related conditions; The patient was treated for shingles, postherpetic neuralgia and other zozter-related conditions; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient (pt.) of unknown age and gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 14-SEP-2014, the pt. was inoculated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route of administration was not specified) for the long-term prevention of shingles and zoster-related conditions as prescribed and/or administered by a pharmacist. On an unspecified date, the pt. experienced shingles, post herpetic neuralgia and other zoster-related conditions (ill-defined disorder). On an unspecified date, the pt. was treated by a health care provider (HCP) for the aforementioned events and was hospitalized due to the events. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the events was not reported. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).
patient complained of dizziness and nausea. given saline crackers and water, no relief after 30 min od observation. Vital signs remain stable  as follows: @1245 BP 125/68, PR 60, O2Sat 100% @1300 BP 122/76, PR of 62, O2sat 100% @1330 BP 126/72, PR of 56, O2sat 98%  Advised to go to urgent care. family contacted